nalbuphine plus naloxone

PreclinicalSmall molecule

UUniversity of California, San Francisco

nalbuphine plus naloxone is one of 16 small molecule programs targeting Facial Pain. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Facial PainActive, not recruiting

ExperimentalTerminated

Facial PainPreclinical

Active, not recruiting

ExperimentalPreclinical

Terminated

Competition

Competitive Landscape

13 competitors in Facial Pain

#DrugCompanyPhaseTrials

Aimovig

Amgen

Approved

1 2

Lexapro

AbbVie

Approved

1 3

Marcaine

IInnocoll

Approved

1 4

Decadron

AAspen Global Incorporated

Approved

1 5

Kenalog

BBassett Healthcare

Approved

1 6

Aspercreme Warming

AAveritas Pharma, Inc.

Approved

—7

Celebrex

PPhiladelphia Eye Associates

Xylocaine

1 9

Ketalar

AAultman Health Foundation

Phase 2

1 10

EXPAREL

Pacira Pharmaceuticals, Inc

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Experimental1 trial

Effect of Nalbuphine and Naloxone on Experimentally Induced Skin Sensitivity

Terminated·UUniversity of California, San Francisco·N/A·NCT00947284·3 enrolled

Facial Pain1 trial

Efficacy of Nalbuphine and Naloxone Administered as Nose Sprays in the Treatment of Orofacial Pain

Terminated·UUniversity of California, San Francisco·N/A·NCT00716807·46 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for nalbuphine plus naloxone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — nalbuphine plus naloxone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for nalbuphine plus naloxone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of California, San Francisco company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of California, San Francisco

nalbuphine plus naloxone

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Experimental1 trial

Facial Pain1 trial

References

Drug Info

Quick Facts

Related News